VSIR and endometrial cancer: Mulati even demonstrated for the first time that VISTA was highly expressed in human ovarian and endometrial cancers, and that the expression on tumor cells of VISTA can inhibit T cell proliferation and cytokine production in vitro and reduce CD8+ T cell infiltration in vivo, and anti-VISTA antibody treatment prolonged the survival time of tumor-bearing mice [92].